Valuation: Geron Corporation

Market Cap 879M 772M 711M 665M 1.25B 82.93B 1.27B 8.53B 3.31B 40.88B 3.3B 3.23B 142B P/E 2026 *
-68.5x
P/E 2027 * 21.1x
Enterprise Value 858M 754M 694M 649M 1.22B 80.95B 1.24B 8.33B 3.23B 39.91B 3.22B 3.15B 139B EV / Sales 2026 *
3.67x
EV / Sales 2027 * 2.13x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.08%
1 week+8.73%
Current month+9.60%
1 month+7.03%
3 months-12.74%
6 months-2.14%
Current year+3.79%
1 week 1.27
Extreme 1.27
1.47
1 month 1.08
Extreme 1.08
1.47
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/05Free

Director

220,000 0.0343%
20/05Free

Director

220,000 0.0343%
20/05Free

Chairman

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-1.08%+8.73%-9.87%-56.65% 889M
+4.43%+2.49%+61.83%+115.25% 52.88B
+1.58%+14.12%+72.87%+85.18% 50.98B
-0.23%-0.98%-14.12%-16.00% 22.81B
+0.98%+9.05%-0.36%+423.40% 22.43B
-0.18%+7.81%+32.56%-13.81% 17.01B
+0.88%+5.78%+30.82%-34.26% 15.91B
+0.68%+2.54%+22.28%+168.03% 13.29B
+3.02%+12.74%+143.33%+308.04% 13.58B
+0.79%+1.59%+85.06%+116.18% 11.75B
Average +1.12%+6.57%+42.44%+109.54% 22.15B
Weighted average by Cap. +1.83%+6.57%+49.35%+119.70%

Financials

2026 *2027 *
Net sales 234M 205M 189M 177M 332M 22.06B 338M 2.27B 879M 10.87B 878M 859M 37.78B 333M 293M 270M 252M 473M 31.43B 481M 3.23B 1.25B 15.5B 1.25B 1.22B 53.85B
Net income -13.95M -12.26M -11.29M -10.56M -19.8M -1.32B -20.17M -135M -52.48M -649M -52.4M -51.25M -2.26B 46.55M 40.89M 37.67M 35.22M 66.06M 4.39B 67.28M 452M 175M 2.17B 175M 171M 7.52B
Net Debt -20.97M -18.42M -16.97M -15.87M -29.76M -1.98B -30.31M -204M -78.87M -975M -78.74M -77.02M -3.39B -169M -148M -137M -128M -240M -15.95B -244M -1.64B -636M -7.86B -635M -621M -27.32B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
25/06/26 USD 1.370 -1.08% 9,545,777
24/06/26 USD 1.385 +2.59% 19,234,596
23/06/26 USD 1.350 +0.75% 13,103,262
22/06/26 USD 1.340 +6.35% 18,713,541
18/06/26 USD 1.260 +2.44% 22,995,891
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.370USD
Average target price
3.400USD
Spread / Average Target
+148.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock